Increased Risk of Lung Metastases in Patients with Giant Cell Bone Tumors: A Systematic Review

Yayan, Josef

doi:10.1007/5584_2019_372

Cited by 9 publications

(7 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially presented as case reports, further studies were conducted on patients with this diagnosis [5 , 6] . Local recurrence of GCTs has been reported to occur in 10% to 25% of cases [2 , 4 , 7 , 8] ; however, some studies have reported higher rates of 60% to 75% for local recurrence [2 , 9 , 10] . Distant metastasis occurs in approximately 16% of GCTs [1] , with rates of distant metastasis to the lungs reported to be less than 5% in several studies [4 , 11] .…”

Section: Introductionmentioning

confidence: 99%

A case report on pulmonary metastasis of giant cell tumor mimicking arteriovenous malformation

Yazdi,

Parviz,

Delazar

et al. 2024

Radiology Case Reports

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A case report on pulmonary metastasis of giant cell tumor mimicking arteriovenous malformation

Yazdi,

Parviz,

Delazar

et al. 2024

Radiology Case Reports

View full text Add to dashboard Cite

“…The clinical features include swelling, pain, and limitations in joint movement [3]. Around half of GCTB arise around the knee joint, either affecting the distal femur or proximal tibia [1]. Tissue biopsy reveals an excess of multinucleated giant cells on a stromal cell background, indicating a diagnosis.…”

Section: Introductionmentioning

confidence: 99%

“…Giant cell tumors of the bone (GCTB) are rare, benign, aggressive, recurrent tumors [ 1 ]. They are most often found at the ends of long bones and account for 5% of all primary bone tumors and 20% of all benign bone tumors [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes in Bone Giant Cell Tumors Treated With Surgical Resection With and Without Denosumab Injection: A Single-Institution Retrospective Study

Alyami¹,

Nazer²,

Bashawieh³

et al. 2022

Cureus

View full text Add to dashboard Cite

Background: Giant cell tumors of the bone (GCTB) are rare, benign, aggressive, recurrent tumors that are most often found at the ends of long bones. They account for 5% of all primary bone tumors and 20% of all benign bone tumors. The clinical features of GCTB include local swelling, pain, and limitations in joint movement. Approximately half of GCTB arise around the knee joint, affecting either the distal femur or proximal tibia. Tissue biopsy reveals an excess of multinucleated giant cells on a stromal cell background, indicating a diagnosis. Intralesional curettage is used to treat GCTB and is associated with minimal disability; however, local recurrence may occur in many patients. Resection and endoprosthetic repair or bone graft reconstruction are often used to treat GCTB near the joint. To our knowledge, there are currently no studies on this topic in the city of Jeddah, where we conducted our study. Our aim was to evaluate the outcome of surgical resection accompanied by denosumab injection compared to that of surgery alone in treating GCTB.Methods: All cases of GCTB at King Abdulaziz Medical City, Jeddah, between January 2008 and December 2018, that fulfilled the inclusion and exclusion criteria were included. All cases of GCTB in the pre-specified period were classified as surgical resection with denosumab injection or surgical resection alone. The outcomes of the two modalities were compared. Recurrence was investigated in patients belonging to both the groups.Results: Twenty-six cases that met the inclusion criteria were included in the study and the data were analyzed. The subjects were divided into two groups: denosumab and surgery (n = 7) and surgery alone (n = 19). Patients treated with denosumab and surgery had a higher recurrence rate (57%); however, the difference was not significant (p = 0.407). Conclusion:Our study showed that when comparing local recurrence after curettage in patients treated with denosumab and patients who did not receive it, preoperative denosumab therapy was associated with an increased incidence of local recurrence. We recommend a systematic review that can include more studies in this field to acquire more definitive results regarding this topic.

show abstract

“…Those studies reported different results due to a small number of patients. [12] The aim of this study is to evaluate the relationship between recurrence and lung metastasis in patients diagnosed with giant cell tumor of bone treated in our clinic and to present the other factors affecting the recurrence.…”

Section: Introductionmentioning

confidence: 99%

Kemiğin dev hücreli tümörlerinde rekürrens ve akciğer metastazı arasındaki ilişki

Yapar

Atalay

Ulucaköy

et al. 2020

Turkish Journal of Clinics and Laboratory

View full text Add to dashboard Cite

Aim:The aim of this study is to evaluate the relationship between recurrence and lung metastasis in patients diagnosed with giant cell tumor of bone treated in our clinic and to present the other factors affecting the recurrence. Material and Methods:The patients who were treated and followed up for a giant cell tumor of the bone between 2002 and 2018 were retrospectively reviewed. A total of 114 patients with a mean age of 31.6 ± 13.3 were included in the study. Results:The mean follow-up period was 63.1 ± 33.4 months. Recurrence occurred in 26.3% (30 patients) of the patients in a mean of 17.1 months, while metastasis in the lung was found in 4.4% (5 patients). When the patients were evaluated according to their recurrence status, lung metastasis was observed in 13.3% of the patients with recurrence, while lung metastasis was observed in 1.2% of the patients without recurrence. Lung metastasis was found to be significantly higher in patients with recurrence than in the group without recurrence (p = 0.017). For lung metastasis, Hazard Ratio (HR) was calculated as 12.8 (95% CI: 1.4-119.5; p = 0.026). Conclusion:Giant cell tumors of the bone are locally aggressive tumors with unpredictable behavior. In our study, when the patients were evaluated according to their recurrence status, lung metastasis was observed in 13.3% of the patients with recurrence, and 1.2% of the patients without recurrence. Lung metastasis was found to be significantly higher in patients with recurrence than in the group without recurrence.

show abstract

Increased Risk of Lung Metastases in Patients with Giant Cell Bone Tumors: A Systematic Review

Cited by 9 publications

References 87 publications

A case report on pulmonary metastasis of giant cell tumor mimicking arteriovenous malformation

A case report on pulmonary metastasis of giant cell tumor mimicking arteriovenous malformation

Outcomes in Bone Giant Cell Tumors Treated With Surgical Resection With and Without Denosumab Injection: A Single-Institution Retrospective Study

Kemiğin dev hücreli tümörlerinde rekürrens ve akciğer metastazı arasındaki ilişki

Contact Info

Product

Resources

About